Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.
Low serum testosterone levels within the first year of androgen-deprivation therapy (ADT) is associated with improved cause-specific survival.
The researchers found that 12% of the participants experienced treatment decisional regret.
Highest risk during first 6 months of ADT among men who had cardiovascular events before treatment.
Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.
Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.
The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.
Prostate cancer progression was delayed by a median 10 months in statin users.
Small study suggests alternating testosterone levels may make hormonal therapy work longer for prostate cancer patients.
Longer cancer-specific and overall survival seen in older men with locally advanced or high-risk PCa
PSA doubling time of 6 months or less and seminal vesicle invasion were significant predictors of biochemical recurrence.
Androgen-deprivation therapy (ADT) for more than 1 year is associated with a 2.5 times higher odds of fracture in prostate cancer patients.
Testosterone replacement therapy (TRT) may lower hemoglobin levels and improve lipid profile in diabetic men with androgen deficiency.
But overall risk of heart-related death risk from prostate cancer treatment is small, researchers say.
Starting docetaxel with androgen deprivation therapy prolonged median overall survival by more than 13 months versus ADT alone.
Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.
The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.
Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.
The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.
The treatment, however, is associated with a decreased risk of all-cause mortality in men at high risk of disease progression.
It is beneficial in terms of muscle strength, cardiorespiratory fitness, functional task performance, lean body mass, and fatigue.
Liberal use of androgen deprivation therapy likely gave prostate cancer patients a fracture risk comparable to that of the cancer itself.
Acute kidney injury was most likely to develop in men receiving combined androgen blockade.
Study reveals lower risk of developing castrate-resistant prostate cancer.
Integrated prostate cancer centers have greater use of intensity modulated radiation therapy.
Testosterone takes a long time to recover, so PSA levels in prostate cancer patients may remain low.
While bone loss and reduction in bone mineral density are well known consequences of ADT, the main concern is increased risk of osteoporotic fractures.
A large, international trial has found intermittent ADT is not equivalent to continuous ADT.
Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.
Nearly 189,000 men with nonmetastatic disease are receiving continuous ADT for six months or more, researchers estimate.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)